Table 2.
Associations of patient, lymphoma, and HIV factors with treatment outcomes for all 1546 patients
| Univariate |
Multivariatea |
|||||
|---|---|---|---|---|---|---|
| Odds ratio (95% CI; P) | Hazard ratio (95% CI; P) |
Odds ratio (95% CI; P) | Hazard ratio (95% CI; P) |
|||
| CR | PFS | OS | CR | PFS | OS | |
| Patient factors | ||||||
| Ageb | 1.01 (1.00–1.02; 0.23) | 0.99 (0.98–1.00; 0.099) | 1.00 (0.99–1.01; 0.88) | 0.99 (0.97–1.01; 0.17) | 1.00 (0.99–1.01; 0.90) | 1.01 (1.00–1.02; 0.08) |
| Sexc | 1.01 (0.75–1.36; 0.93) | 0.88 (0.70–1.09; 0.25) | 0.89 (0.74–1.07; 0.21) | 0.80 (0.52–1.24; 0.32) | 1.07 (0.81–1.40; 0.63) | 1.08 (0.85–1.36; 0.53) |
| Lymphoma factors | ||||||
| Histology | ||||||
| DLBCL | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
| BL/BLL | 1.04 (0.80–1.34; 0.076) | 1.22 (1.02–1.45; 0.03) | 0.93 (0.80–1.09; 0.39) | 0.71 (0.48–1.07; 0.10) | 1.36 (1.06–1.74; 0.02) | 1.18 (0.94–1.47; 0.16) |
| Otherd | 0.84 (0.53–1.35; 0.49) | 1.38 (.098–1.88; 0.053) | 1.21 (0.89–1.61; 0.20) | 0.39 (0.15–0.99; 0.047) | 1.61 (0.93–2.62; 0.07) | 1.17 (0.71–1.83; 0.52) |
| aaIPIe | 0.57 (0.50–0.66; <0.001) | 1.35 (1.22–1.49; <0.001) | 1.39 (1.28–1.51; <0.001) | 0.48 (0.40–0.58; <0.001) | 1.58 (1.40–1.80; <0.001) | 1.52 (1.37–1.69; <0.001) |
| HIV factors | ||||||
| CD4 count <50 cells/mm3 | 0.50 (0.37–0.69; <0.001) | 1.37 (1.08–1.70; 0.006) | 1.85 (1.54–2.22; <0.001) | 0.42; (0.26–0.67; <0.001) | 0.76 (0.56–1.05; 0.09) | 1.78; (1.38–2.27; <0.001) |
| Prior history of AIDS | 0.54 (0.42–0.68; <0.001) | 1.05 (0.88–1.26; 0.57) | 1.28 (1.10–1.49; 0.001) | 0.66 (0.45–0.96; 0.03) | 1.16 (0.91–1.48; 0.23) | 1.25 (1.01–1.53; 0.04) |
aAll estimates in the multivariate analysis were adjusted for rituximab use, treatment, concurrent use of cART, age, sex, histological subtype, age-adjusted international prognostic index, CD4 count at baseline, prior history of AIDS, and enrollment period.
bAssociations are determined per each additional year.
cReference variable is male.
d‘Other’ histologies include unknown (N = 4), non-classifiable (N = 56), other-not otherwise specified (N = 23), anaplastic large-cell lymphoma (N = 4), and lymphoplasmacytoid lymphoma (N = 1).
eAssociations are determined per 1 point increase in score (range 0–3).
CR, complete response; PFS, progression-free survival; OS, overall survival; DLBCL diffuse large B-cell lymphoma; BL, Burkitt lymphoma; BLL, Burkitt-like lymphoma; aaIPI, age-adjusted International Prognostic Index.